We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Khalid Athar M.D., Culpeper Surgery Center.
Recruitment status was:  Enrolling by invitation
Sponsor:
ClinicalTrials.gov Identifier:
NCT01514175
First Posted: January 23, 2012
Last Update Posted: May 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cumberland Pharmaceuticals
Information provided by (Responsible Party):
Khalid Athar M.D., Culpeper Surgery Center
  Purpose
The primary objective of this study is to compare the efficacy of a single dose of intravenous ibuprofen compared to a single dose of ketorolac for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS).

Condition Intervention Phase
Chronic Pelvic Pain Drug: IV Ibuprofen Drug: IV Ketorolac Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac

Resource links provided by NLM:


Further study details as provided by Khalid Athar M.D., Culpeper Surgery Center:

Primary Outcome Measures:
  • The efficacy of a single dose of intravenous ibuprofen compared to a single dose of ketorolac for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS). [ Time Frame: One Year ]

Secondary Outcome Measures:
  • Amount of and time to rescue medication in the postoperative period between IV ibuprofen and IV ketorolac treatment groups [ Time Frame: 1 Year ]
  • Time to mobility in the postoperative period between IV ibuprofen and IV ketorolac treatment groups [ Time Frame: One Year ]
  • Time to discharge in the postoperative period between IV ibuprofen and IV ketorolac treatment groups [ Time Frame: One Year ]
  • Incidence of adverse events between IV ibuprofen and IV ketorolac treatment groups [ Time Frame: One Year ]

Enrollment: 50
Study Start Date: January 2012
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ibuprofen versus ketoralac
IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
Drug: IV Ibuprofen
Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Other Name: IV Caldolor
Drug: IV Ketorolac
Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Other Name: IV Toradol

Detailed Description:

The primary objective of this study is to compare the efficacy of a single dose of intravenous ibuprofen compared to a single dose of ketorolac for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS).

The secondary objectives of this study are:

  • To compare amount of and time to rescue medication in the postoperative period between IV ibuprofen and IV ketorolac treatment groups.
  • To compare time to mobility in the postoperative period between IV ibuprofen and IV ketorolac treatment groups.
  • To compare time to discharge in the postoperative period between IV ibuprofen and IV ketorolac treatment groups.
  • To compare the incidence of adverse events between IV ibuprofen and IV ketorolac treatment groups.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a preoperative diagnosis which is inclusive of chronic pelvic pain scheduled for Laparoscopic Surgery

Exclusion Criteria:

  • Inadequate IV access.
  • History of allergy or hypersensitivity to any component of IVIb,ketorolac, aspirin (or aspirin related products), NSAIDs, or COX-2 inhibitors.
  • Less than 18 years of age or Greater than 65 years of age.
  • Use of analgesics, including NSAIDs, less than 12 hours prior to surgery.
  • Patients with active, clinically significant anemia.
  • History or evidence of asthma or heart failure.
  • Pregnant.
  • Inability to understand the requirements of the study, be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]), and agree to abide by the study restrictions and to return for the required assessments.
  • Refusal to provide written authorization for use and disclosure of protected health information.
  • Patients with a history of Chronic Pain Conditions or Syndromes excluding patients with Chronic Pelvic Pain.
  • Patients with known OSA
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514175


Locations
United States, Virginia
Culpeper Surgery Center
Culpeper, Virginia, United States, 22701
Sponsors and Collaborators
Culpeper Surgery Center
Cumberland Pharmaceuticals
Investigators
Principal Investigator: Khalid Athar, MD Culpeper Regional Health Systems
  More Information

Responsible Party: Khalid Athar M.D., Medical Director, Culpeper Surgery Center
ClinicalTrials.gov Identifier: NCT01514175     History of Changes
Other Study ID Numbers: KACW1
First Submitted: June 14, 2011
First Posted: January 23, 2012
Last Update Posted: May 16, 2012
Last Verified: May 2012

Keywords provided by Khalid Athar M.D., Culpeper Surgery Center:
Ketorolac
Caldolor
Chronic Pelvic Pain

Additional relevant MeSH terms:
Pelvic Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Ibuprofen
Ketorolac
Ketorolac Tromethamine
Analgesics
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action